Condition
QTc Interval
Total Trials
5
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 5 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (3)
Trial Status
Completed5
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06601192Phase 1Completed
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
NCT05865262Completed
Protocol TRANS and QT Repolarization
NCT05478278Phase 1CompletedPrimary
An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics
NCT03418077Not ApplicableCompletedPrimary
Post-Exercise Cardiovascular Responses Following Energy Drink Consumption
NCT01327066Phase 1CompletedPrimary
Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose
Showing all 5 trials